← All companies
Roivant Sciences Ltd.
ROIV - CIK 0001635088
Market cap$20.43 B
Rank#607
SEC filings868
Roivant Sciences Ltd. trades as ROIV and has a market capitalization of $20.43 B, making it the #607 largest US-listed company by market value. In its fiscal 2026 annual report the company posted revenue of $8.26M, down 71.6% from the prior year and net income of -$299.77M. This page tracks Roivant Sciences Ltd. through 868 SEC filings, with financial statements and metrics updated as new reports are filed.
Key metrics
Revenue (latest FY)$8.26MFY 2026
Net income (latest FY)-$299.77MFY 2026
Operating cash flow (latest FY)-$750.35MFY 2026
Total assets (latest FY)$5.71BFY 2025
Net margin-3629.2%latest FY
Financial performance
Over the last 5 fiscal years Roivant Sciences Ltd.'s revenue declined from $23.80M to $8.26M, a compound annual decline rate of 19.1%. Net profit margin compressed from -3400.9% to -3629.2% over the same period - every figure below comes from the company's audited annual filings.
Key statistics
- Market cap
- $20.43 B
- Share price (derived)market cap / shares outstanding
- $28.41
- EPS (diluted)FY 2026
- $-0.54
- Shares outstandingas of 2026-05-12
- 0.72B
- Total equityas of 2026-03-31
- $4.53B
- Return on equity
- -6.6%
- Long-term debtas of 2024-06-30
- $311.72M
- Cash & equivalentsas of 2026-03-31
- $1.42B
Latest filings
| Filing | Type | Filed |
|---|---|---|
| Insider sale notice | 144 | 2026-05-22 |
| Insider trade | 4 | 2026-05-22 |
| Insider trade | 4 | 2026-05-22 |
| Annual report | 10-K | 2026-05-20 |
| Major company event | 8-K | 2026-05-20 |
| Employee stock plan | S-8 | 2026-05-20 |
| SCHEDULE 13G/A | - | 2026-05-06 |
| Insider trade | 4 | 2026-04-22 |
Recent press releases
- Priovant Expands Brepocitinib Development Program NEW Phase 2B32026-04-02
Priovant Expands Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP) | Roivant Sciences Ltd.
- Immunovant’s Phase 3 studies of batoclimab in thyroid eye disease (TED) each failed to meet their primary endpoint; safety results were consistent with previous findings2026-04-02
Roivant Announces Expansion of Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP) and Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED) | Roivant Sciences Ltd.
- Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 and Provides Business Update | Roivant Sciences Ltd.2026-03-31
IMVT-1402 showed clinically meaningful response rates of 72.7% ACR20, 54.5% ACR50 and 35.8% ACR70 at Week 16 in the open label period of its trial in difficult-to-treat rheumatoid arthritis (D2T RA); Immunovant will provide further updates on this program in the second half of calendar year 2026
- Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 and Provide Business Update on Wednesday, May 20, 2026 | Roivant Sciences Ltd.2026-03-31
To access the conference call by phone, please register online using this registration link . The presentation and webcast details will also be available under “Events & Presentations” in the Investors section of the Roivant website at https://investor.roivant.com/news-events/events. The archived webcast will be available on Roivant’s website after the conference call.
Similar companies
The largest companies sharing Roivant Sciences Ltd.'s SEC industry classification (pharmaceutical preparations).
Frequently asked questions
What is Roivant Sciences Ltd.'s market cap?
Roivant Sciences Ltd. (ROIV) has a market capitalization of $20.43 B as of 2026-06-10, ranking #607 among US-listed companies.
How much revenue does Roivant Sciences Ltd. make?
Roivant Sciences Ltd. reported revenue of $8.26M for fiscal year 2026, a decrease of 71.6% year over year.
Is Roivant Sciences Ltd. profitable?
In its latest fiscal year Roivant Sciences Ltd. reported a net loss of $299.77M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.